PUBLISHER: Meticulous Research | PRODUCT CODE: 2138403
PUBLISHER: Meticulous Research | PRODUCT CODE: 2138403
Epigenetics Market Size, Share, and Industry Analysis by Offering, Method, Application, End User, and Geography - Global Forecast to 2036
The global Epigenetics Market was valued at USD 2,379.0 million in 2025 and is estimated to reach USD 2,626.5 million in 2026. The market is projected to reach USD 8,528.9 million by 2036, registering a CAGR of 12.5% during the forecast period (2026-2036). This report provides a comprehensive assessment of the rapidly evolving epigenetics market by examining DNA methylation, histone modification, RNA modification, chromatin analysis, epigenetic biomarkers, methylation-based cancer screening, epigenetic drug development, single-cell epigenomics, competitive developments, and future growth opportunities across the life sciences and clinical diagnostics landscape.
Epigenetics involves heritable changes in gene activity that occur without changes to the underlying DNA sequence. Epigenetic analysis tools detect, map, and quantify modifications such as DNA methylation, histone modification, RNA modification, chromatin accessibility, and chromatin organization. Kits, reagents, instruments, services, and software used in these workflows support cancer research, biomarker discovery, drug discovery and development, disease research, clinical diagnostics, methylation-based cancer detection, and the development of epigenetic and chromatin-targeted therapies.
The growth of this market is mainly driven by the rising cancer burden and growing use of epigenetic biomarkers in oncology, the expanding pipeline and approvals of epigenetic and chromatin-targeted therapies, advances in epigenomic technologies, and the clinical adoption of methylation-based cancer detection. DNA methylation is chemically stable, can be measured in blood, stool, and tissue, and can change early in tumor development, making it valuable for cancer screening, classification, and monitoring. In addition, multi-cancer early detection, liquid biopsy, epigenetic editing therapeutics, single-cell and spatial multiomics, and expanding research and diagnostic capabilities in emerging markets are expected to create significant opportunities for market participants.
This report delivers an in-depth analysis of the market by evaluating offering types, epigenetic methods, application areas, end users, technological innovations, clinical adoption trends, regulatory developments, research funding, and competitive strategies shaping industry growth. It assesses how enzymatic methyl-seq, five-base sequencing, native methylation detection, CUT&RUN, CUT&Tag, single-cell chromatin analysis, multiomic assays, artificial intelligence, and integrated epigenomic software are improving sensitivity, reducing input requirements, and expanding the clinical and research utility of epigenetic analysis. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business, investment, product development, and market-entry decisions.
Market Dynamics
The rising global cancer burden and increasing use of epigenetic biomarkers in oncology remain among the primary drivers of the epigenetics market. Aberrant DNA methylation can occur early in tumor development and may provide information about cancer presence, tissue of origin, disease classification, treatment response, and minimal residual disease. The increasing use of methylation-based assays in cancer screening, liquid biopsy, tumor profiling, and disease monitoring is therefore generating demand for kits, enzymes, sequencing workflows, instruments, and bioinformatics software.
The expanding pipeline and approval of epigenetic and chromatin-targeted therapies are further accelerating market growth. Menin inhibitors, histone deacetylase inhibitors, and other chromatin-targeted treatments are entering clinical practice, while new drug programs increasingly require epigenetic assays, antibodies, enzymes, histone substrates, sequencing-based tests, and chromatin profiling throughout discovery and development. The clinical advancement of epigenetic editing therapies is also creating new demand for methylation analysis, off-target profiling, chromatin assays, and specialized data analysis.
Advances in epigenomic technologies are reshaping the competitive landscape. Enzymatic methyl-seq, five-base sequencing, and native methylation detection on PacBio and Oxford Nanopore long-read platforms can reduce DNA damage and, in some cases, provide genetic and methylation information from the same molecule. These technologies are increasingly being evaluated as alternatives to conventional bisulfite conversion. In parallel, CUT&RUN and CUT&Tag require fewer cells and less sequencing than traditional chromatin immunoprecipitation sequencing, supporting their adoption in low-input and single-cell applications.
Clinical adoption of methylation-based cancer detection is creating a transition from a specialized research-tool market toward a clinical testing market. FDA-approved tests, Medicare payment pathways, clinical evidence, and ongoing evaluation of multi-cancer early detection assays are increasing awareness of methylation-based diagnostics. As hospitals and diagnostic laboratories expand clinical sequencing and oncology testing, demand for validated methylation reagents, instruments, services, and software is expected to increase.
The expansion of single-cell and spatial multiomics is creating additional opportunities. Multiomic workflows can integrate methylation, chromatin accessibility, histone marks, and gene expression to provide a more comprehensive view of cellular states and disease mechanisms. These approaches are increasingly valuable in drug discovery, tumor biology, developmental research, precision medicine, and biomarker discovery. Integrated software and machine learning tools are also helping researchers analyze increasingly large and complex epigenomic datasets.
Despite favorable market conditions, high technology and workflow complexity remain important restraints. Genome-wide epigenetic analysis requires specialized instruments, sequencing capacity, low-input sample handling, and advanced bioinformatics. Different methylation methods may not produce identical results, making cross-platform comparison, standardization, and validation difficult. The shortage of trained bioinformatics personnel can also limit adoption among smaller laboratories and institutions.
Research funding pressure and capital requirements represent additional challenges. Academic and government laboratories are important users of epigenetics tools, but instrument purchasing can fluctuate with public funding, grant availability, and research priorities. High-end single-cell, spatial, and long-read systems may require substantial capital investment, while services and outsourced sequencing can be more accessible to budget-constrained users. In addition, older methods such as bisulfite conversion, sonication, PCR, and high-resolution melt analysis may face substitution from integrated sequencing and advanced enzymatic workflows.
The market nevertheless presents substantial opportunities through methylation-based liquid biopsy, multi-cancer early detection, epigenetic editing, enzymatic and native long-read methylation technologies, single-cell chromatin analysis, epigenomic software, and expansion in Asia-Pacific. Companies that offer low-input, high-throughput, clinically validated, and easy-to-analyze solutions are expected to be well positioned to benefit from the continued integration of epigenetics into oncology, drug development, and precision medicine.
Segment Analysis
The report provides detailed market analysis across offering, method, application, end user, and geography, enabling stakeholders to identify high-growth opportunities and evolving trends in epigenomic research, methylation-based diagnostics, cancer testing, chromatin biology, drug discovery, and clinical laboratory adoption.
Based on offering, the market is segmented into Kits & Reagents, comprising kits and assays, antibodies, proteins and enzymes, and other reagents, as well as Instruments & Accessories, Services, and Software. Kits & Reagents are expected to account for the largest market share of 69.4% in 2026, attributed to the recurring use of kits, antibodies, enzymes, and other reagents in epigenetic experiments, research workflows, drug-development studies, and clinical tests. However, the Software segment is projected to register the highest CAGR of 15.1% during the forecast period, driven by integrated analysis platforms, machine learning, increasingly complex multiomic datasets, and the growing need for scalable interpretation of methylation and chromatin data.
Based on method, the market is segmented into DNA Methylation, including bisulfite conversion, high-resolution melt analysis, immunoprecipitation, and other DNA methylation methods, as well as Histone Modification, RNA Modification, Polymerase Chain Reaction, Chromatin Analysis, Sonication, and Other Methods. DNA Methylation is expected to account for the largest share of 34.4% of the market in 2026, reflecting its central role in cancer research, biomarker discovery, screening tests, disease classification, and monitoring. However, Chromatin Analysis is projected to register the highest CAGR of 15.3% during the forecast period, supported by the adoption of CUT&RUN, CUT&Tag, single-cell chromatin assays, spatial methods, and multiomic workflows. Within DNA methylation, enzymatic, five-base, and native long-read methods are projected to grow at 19.0%.
Based on application, the market is segmented into Oncology and Non-oncology. Oncology is expected to account for the larger share of 78.4% of the Epigenetics Market in 2026 and is also projected to register the higher CAGR of 12.9% during the forecast period. The large share and strong growth of this segment are supported by the rising global cancer burden, increasing use of methylation-based cancer screening, minimal residual disease testing, tumor profiling, liquid biopsy, and development of epigenetic cancer drugs. Non-oncology applications continue to support demand through research in developmental biology, metabolic disease, neurological disorders, aging, and other disease areas.
Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Hospitals & Diagnostic Laboratories. Pharmaceutical & Biotechnology Companies are expected to account for the largest market share of 73.5% in 2026, due to the extensive use of epigenetic assays in drug discovery, biomarker development, clinical research, epigenetic drug development, and advanced therapy programs. However, Hospitals & Diagnostic Laboratories are projected to register the highest CAGR of 17.3% during the forecast period, driven by the expansion of methylation-based cancer screening, clinical sequencing, diagnostic testing, accreditation requirements, and the growing use of epigenetic biomarkers in oncology.
Regional Analysis
The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider cancer burden, pharmaceutical and biotechnology research, clinical diagnostics, national genomic programs, epigenetic drug development, sequencing infrastructure, reimbursement frameworks, academic funding, and investments influencing market growth.
North America is expected to account for the largest share of 50.0% of the global Epigenetics Market in 2026. The region's leadership is attributed to the concentration of pharmaceutical and biotechnology companies, research institutions, leading epigenetics suppliers, and advanced clinical laboratories in the U.S. The approval and reimbursement of methylation-based cancer screening tests, the development of menin inhibitors and other epigenetic drugs, strong oncology research, and the presence of major sequencing and life-science companies are further supporting regional growth. The U.S. is expected to account for 90.7% of the North American market in 2026.
Europe is expected to account for the second-largest share of 25.0% of the epigenetics market in 2026. The region's significant share is supported by its large pharmaceutical and academic research base, national genomic and cancer programs, and the presence of major suppliers such as Merck KGaA and QIAGEN in Germany and Oxford Nanopore Technologies in the U.K. The U.K. hosts a major randomized trial of a multi-cancer early detection test, while Germany is expected to account for the largest share of the European market, at 30.2%.
Asia-Pacific is projected to register the highest CAGR of 13.7% during the forecast period. Growth in the region is driven by its large cancer burden, with Asia accounting for approximately 49% of new cancer cases worldwide in 2022, the scale of sequencing service providers in China, growing research investment in India, and the development of methylation-based cancer tests by domestic companies. China is expected to account for the largest share of the regional market in 2026, at 49.5%, and is projected to register the highest CAGR of any country, at 15.0%. Increasing investments in clinical diagnostics, sequencing, cancer research, and local life-science infrastructure are expected to create substantial opportunities.
Latin America is expected to account for a share of 2.4% of the epigenetics market in 2026. The regional market is driven by growing cancer research, pharmaceutical clinical trial activity, and national genomics initiatives such as Genomas Brasil. Brazil, which records approximately 704,000 new cancer cases per year, accounts for most regional demand. However, limited research budgets are expected to favor lower-cost methods, collaborative research, and outsourced sequencing services.
The Middle East & Africa is expected to account for a share of 1.2% of the epigenetics market in 2026. Growth is being supported by national genome programs in the Gulf states, including the Emirati Genome Programme, which has sequenced more than 800,000 genomes, as well as investments in genomic medicine, cancer research, and clinical laboratory infrastructure. However, epigenetics research capacity remains limited in many African markets, creating both adoption challenges and long-term development opportunities.
Competitive Landscape
The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading market participants, their kits and reagent portfolios, epigenetic instruments, sequencing and single-cell platforms, software offerings, testing services, product launches, partnerships, acquisitions, licensing activities, geographic expansion initiatives, research and development investments, and recent business developments.
Competitive benchmarking enables stakeholders to evaluate companies based on product performance, input requirements, assay sensitivity, workflow simplicity, methylation and chromatin capabilities, multiomic integration, data analysis, clinical validation, intellectual property, service support, and pricing. The study also analyzes how market participants are responding to the transition toward methylation-based diagnostics, enzymatic and five-base sequencing, native long-read methylation, low-input chromatin analysis, single-cell epigenomics, artificial intelligence, and integrated sequencing workflows.
Between January 2025 and September 2026, profiled companies reported numerous strategic developments, led by product and service launches, acquisitions, and partnerships and licensing activities. Key companies profiled in the report include Merck KGaA, 10x Genomics, Inc., Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN N.V., New England Biolabs, Inc., EpiCypher, Inc., Pacific Biosciences of California, Inc., Bio-Rad Laboratories, Inc., Revvity, Inc., Active Motif, Inc., and Zymo Research Corporation.
How This Report Helps
Provides accurate market size estimates and long-term forecasts for the global epigenetics market.
Evaluates the impact of cancer burden, epigenetic biomarkers, methylation-based screening, epigenetic drugs, and advanced epigenomic technologies on market growth.
Identifies high-growth opportunities across offerings, methods, applications, end users, and geographic regions.
Analyzes emerging technology trends in enzymatic methyl-seq, five-base sequencing, native long-read methylation, CUT&RUN, CUT&Tag, single-cell epigenomics, spatial multiomics, and AI-enabled data analysis.
Assesses the influence of clinical validation, reimbursement, research funding, laboratory infrastructure, bioinformatics requirements, and method standardization on adoption.
Benchmarks leading companies based on product portfolios, assay performance, platform capabilities, innovation strategies, clinical positioning, and competitive presence.
Supports product development, investment planning, partnership evaluation, market entry, commercialization, and business expansion strategies.
Delivers actionable market intelligence for life-science companies, pharmaceutical and biotechnology companies, diagnostic laboratories, hospitals, academic researchers, sequencing providers, investors, distributors, and healthcare organizations.
Key Questions Answered
What is the current size of the global epigenetics market, and how is it expected to evolve through 2036?
Which technological, clinical, regulatory, and economic factors are driving market growth?
What are the major drivers, restraints, opportunities, and challenges influencing industry development?
Which offering, method, application, end-user, and regional segments are expected to experience the strongest growth?
Why are Kits & Reagents expected to account for the largest offering share, and why is Software projected to grow fastest?
How will DNA methylation, enzymatic methyl-seq, five-base sequencing, native long-read methylation, and chromatin analysis influence market development?
How are methylation-based cancer screening, liquid biopsy, multi-cancer early detection, and epigenetic drugs affecting demand for epigenetics tools?
Which geographic markets present the most attractive business opportunities for epigenetics companies?
How are single-cell and spatial multiomics, epigenetic editing, and artificial intelligence changing research and clinical workflows?
Who are the leading companies operating in the market, and what competitive strategies are they adopting?
What recent product launches, partnerships, acquisitions, licensing agreements, clinical developments, and technological innovations are shaping the competitive landscape?
How can stakeholders leverage market intelligence from this report to support investment decisions, product development, competitive benchmarking, and long-term business strategy?
TABLE OF CONTENTS
1. Introduction
- 1.1. Market Definition & Scope
- 1.2. Market Ecosystem
- 1.3. Currency & Limitations
- 1.4. Key Stakeholders
2. Research Methodology
- 2.1. Research Approach
- 2.2. Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
- 2.3. Market Assessment
- 2.3.1. Market Size Estimation
- 2.3.2. Bottom-Up Approach
- 2.3.3. Top-Down Approach
- 2.3.4. Growth Forecast
- 2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
- 4.1. Overview
- 4.2. Factors Affecting Market Growth
- 4.2.1. Drivers
- 4.2.1.1. Rising Cancer Burden and Growing Use of Epigenetic Biomarkers in Oncology
- 4.2.1.2. Growing Pipeline and Approvals of Epigenetic and Chromatin-Targeted Therapies
- 4.2.1.3. Advances in Epigenomic Technologies
- 4.2.1.4. Clinical Adoption of Methylation-Based Cancer Detection
- 4.2.2. Restraints
- 4.2.2.1. High Cost of Instruments and Sequencing-Based Epigenomic Analysis
- 4.2.2.2. Constrained Research Funding
- 4.2.3. Opportunities
- 4.2.3.1. Multi-Cancer Early Detection and Liquid Biopsy
- 4.2.3.2. Epigenetic Editing Therapeutics
- 4.2.3.3. Single-Cell and Spatial Multiomics
- 4.2.3.4. Emerging Markets
- 4.2.4. Challenges
- 4.2.4.1. Data Complexity, Standardization and Bioinformatics Requirements
- 4.2.4.2. Clinical Validation and Evidence Requirements
- 4.2.1. Drivers
- 4.3. Key Trends
- 4.3.1. Shift from Bisulfite to Enzymatic and Native Methylation Detection
- 4.3.2. CUT&RUN and CUT&TAG Replacing Chromatin Immunoprecipitation
- 4.3.3. Multiomics, Artificial Intelligence and 3D Genomics
- 4.4. Regulatory Analysis
- 4.4.1. North America
- 4.4.2. Europe
- 4.4.3. Asia-Pacific
- 4.4.4. Latin America
- 4.4.5. Middle East & Africa
- 4.5. Pricing Analysis
- 4.6. Porter's Five Forces Analysis
- 4.6.1. Bargaining Power of Buyers
- 4.6.2. Bargaining Power of Suppliers
- 4.6.3. Threat of Substitutes
- 4.6.4. Threat of New Entrants
- 4.6.5. Degree of Competition
- 4.7. Value Chain Analysis
- 4.7.1. Research & Development
- 4.7.2. Raw Material & Component Supply
- 4.7.3. Manufacturing
- 4.7.4. Distribution & Services
- 4.7.5. End Use
5. Epigenetics Market Assessment, by Offering
- 5.1. Overview
- 5.2. Kits & Reagents
- 5.2.1. Kits & Assays
- 5.2.2. Antibodies
- 5.2.3. Proteins & Enzymes
- 5.2.4. Other Reagents
- 5.3. Instruments & Accessories
- 5.4. Services
- 5.5. Software
6. Epigenetics Market Assessment, by Method
- 6.1. Overview
- 6.2. DNA Methylation
- 6.2.1. Bisulfite Conversion
- 6.2.2. High-Resolution Melt (HRM) Analysis
- 6.2.3. Immunoprecipitation
- 6.2.4. Other DNA Methylation Methods
- 6.3. Histone Modification
- 6.4. RNA Modification
- 6.5. Polymerase Chain Reaction (PCR)
- 6.6. Chromatin Analysis
- 6.7. Sonication
- 6.8. Other Methods
7. Epigenetics Market Assessment, by Application
- 7.1. Overview
- 7.2. Oncology
- 7.3. Non-Oncology
8. Epigenetics Market Assessment, by End User
- 8.1. Overview
- 8.2. Pharmaceutical & Biotechnology Companies
- 8.3. Academic & Research Institutes
- 8.4. Hospitals & Diagnostic Laboratories
9. Epigenetics Market Assessment, by Geography
- 9.1. Overview
- 9.2. North America
- 9.2.1. U.S.
- 9.2.2. Canada
- 9.3. Europe
- 9.3.1. Germany
- 9.3.2. France
- 9.3.3. U.K.
- 9.3.4. Italy
- 9.3.5. Spain
- 9.3.6. Rest of Europe
- 9.4. Asia-Pacific
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. India
- 9.4.4. Rest of Asia-Pacific
- 9.5. Latin America
- 9.6. Middle East & Africa
10. Competitive Landscape
- 10.1. Overview
- 10.2. Key Growth Strategies
- 10.3. Competitive Benchmarking
- 10.4. Competitive Dashboard
- 10.4.1. Industry Leaders
- 10.4.2. Market Differentiators
- 10.4.3. Vanguards
- 10.4.4. Emerging Companies
- 10.5. Market Ranking Analysis (2025)
- 10.5.1. Illumina, Inc. (U.S.)
- 10.5.2. Merck KGaA (Germany)
- 10.5.3. Thermo Fisher Scientific Inc. (U.S.)
- 10.5.4. QIAGEN N.V. (Netherlands)
- 10.5.5. 10x Genomics, Inc. (U.S.)
11. Company Profiles
- 11.1. Merck KGaA (Germany)
- 11.1.1. Company Overview
- 11.1.2. Financial Overview
- 11.1.3. Product Portfolio
- 11.1.4. Strategic Developments
- 11.1.5. SWOT Analysis
- 11.2. 10x Genomics, Inc. (U.S.)
- 11.2.1. Company Overview
- 11.2.2. Financial Overview
- 11.2.3. Product Portfolio
- 11.2.4. Strategic Developments
- 11.2.5. SWOT Analysis
- 11.3. Thermo Fisher Scientific Inc. (U.S.)
- 11.3.1. Company Overview
- 11.3.2. Financial Overview
- 11.3.3. Product Portfolio
- 11.3.4. Strategic Developments
- 11.3.5. SWOT Analysis
- 11.4. Illumina, Inc. (U.S.)
- 11.4.1. Company Overview
- 11.4.2. Financial Overview
- 11.4.3. Product Portfolio
- 11.4.4. Strategic Developments
- 11.4.5. SWOT Analysis
- 11.5. QIAGEN N.V. (Netherlands)
- 11.5.1. Company Overview
- 11.5.2. Financial Overview
- 11.5.3. Product Portfolio
- 11.5.4. Strategic Developments
- 11.5.5. SWOT Analysis
- 11.6. New England Biolabs, Inc. (U.S.)
- 11.6.1. Company Overview
- 11.6.2. Financial Overview
- 11.6.3. Product Portfolio
- 11.6.4. Strategic Developments
- 11.6.5. SWOT Analysis
- 11.7. EpiCypher, Inc. (U.S.)
- 11.7.1. Company Overview
- 11.7.2. Financial Overview
- 11.7.3. Product Portfolio
- 11.7.4. Strategic Developments
- 11.7.5. SWOT Analysis
- 11.8. Pacific Biosciences of California, Inc. (U.S.)
- 11.8.1. Company Overview
- 11.8.2. Financial Overview
- 11.8.3. Product Portfolio
- 11.8.4. Strategic Developments
- 11.8.5. SWOT Analysis
- 11.9. Bio-Rad Laboratories, Inc. (U.S.)
- 11.9.1. Company Overview
- 11.9.2. Financial Overview
- 11.9.3. Product Portfolio
- 11.9.4. Strategic Developments
- 11.9.5. SWOT Analysis
- 11.10. Revvity, Inc. (U.S.)
- 11.10.1. Company Overview
- 11.10.2. Financial Overview
- 11.10.3. Product Portfolio
- 11.10.4. Strategic Developments
- 11.10.5. SWOT Analysis
- 11.11. Active Motif, Inc. (U.S.)
- 11.11.1. Company Overview
- 11.11.2. Financial Overview
- 11.11.3. Product Portfolio
- 11.11.4. Strategic Developments
- 11.11.5. SWOT Analysis
- 11.12. Zymo Research Corporation (U.S.)
- 11.12.1. Company Overview
- 11.12.2. Financial Overview
- 11.12.3. Product Portfolio
- 11.12.4. Strategic Developments
- 11.12.5. SWOT Analysis
12. Appendix
- 12.1. Available Customization
- 12.2. Related Reports
LIST OF TABLES
List of Tables
- Table 1 Epigenetics Market Ecosystem
- Table 2 Key Secondary Sources
- Table 3 Epigenetics: DNA Methylation Detection Methods Compared
- Table 4 Epigenetics: Key Regulatory Frameworks, by Region
- Table 5 Epigenetics: Indicative Prices of Selected Tests and Sequencing
- Table 6 Epigenetics Market: Value Chain, by Stage
- Table 7 Global Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 8 Global Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 9 Global Epigenetics Kits & Reagents Market, by Country/Region, 2024-2036 (USD Million)
- Table 10 Epigenetics: Selected Kits and Assays Launched, 2025-2026
- Table 11 Global Epigenetics Kits & Assays Market, by Country/Region, 2024-2036 (USD Million)
- Table 12 Global Epigenetics Antibodies Market, by Country/Region, 2024-2036 (USD Million)
- Table 13 Global Epigenetics Proteins & Enzymes Market, by Country/Region, 2024-2036 (USD Million)
- Table 14 Global Other Epigenetics Reagents Market, by Country/Region, 2024-2036 (USD Million)
- Table 15 Global Epigenetics Instruments & Accessories Market, by Country/Region, 2024-2036 (USD Million)
- Table 16 Global Epigenetics Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 17 Global Epigenetics Software Market, by Country/Region, 2024-2036 (USD Million)
- Table 18 Global Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 19 Global Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 20 Global Epigenetics Market for DNA Methylation, by Country/Region, 2024-2036 (USD Million)
- Table 21 Global Epigenetics Market for Bisulfite Conversion, by Country/Region, 2024-2036 (USD Million)
- Table 22 Global Epigenetics Market for High-Resolution Melt (HRM) Analysis, by Country/Region, 2024-2036 (USD Million)
- Table 23 Global Epigenetics Market for Immunoprecipitation, by Country/Region, 2024-2036 (USD Million)
- Table 24 Global Epigenetics Market for Other DNA Methylation Methods, by Country/Region, 2024-2036 (USD Million)
- Table 25 Global Epigenetics Market for Histone Modification, by Country/Region, 2024-2036 (USD Million)
- Table 26 Global Epigenetics Market for RNA Modification, by Country/Region, 2024-2036 (USD Million)
- Table 27 Global Epigenetics Market for Polymerase Chain Reaction (PCR), by Country/Region, 2024-2036 (USD Million)
- Table 28 Global Epigenetics Market for Chromatin Analysis, by Country/Region, 2024-2036 (USD Million)
- Table 29 Global Epigenetics Market for Sonication, by Country/Region, 2024-2036 (USD Million)
- Table 30 Global Epigenetics Market for Other Methods, by Country/Region, 2024-2036 (USD Million)
- Table 31 Global Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 32 Global Epigenetics Market for Oncology, by Country/Region, 2024-2036 (USD Million)
- Table 33 Epigenetics: Epigenetic Editing Therapies in Clinical Development
- Table 34 Global Epigenetics Market for Non-Oncology, by Country/Region, 2024-2036 (USD Million)
- Table 35 Global Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 36 Global Epigenetics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2024-2036 (USD Million)
- Table 37 Global Epigenetics Market for Academic & Research Institutes, by Country/Region, 2024-2036 (USD Million)
- Table 38 Global Epigenetics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2024-2036 (USD Million)
- Table 39 Global Epigenetics Market, by Region, 2024-2036 (USD Million)
- Table 40 North America: Epigenetics Market, by Country/Region, 2024-2036 (USD Million)
- Table 41 North America: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 42 North America: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 43 North America: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 44 North America: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 45 North America: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 46 North America: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 47 U.S.: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 48 U.S.: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 49 U.S.: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 50 U.S.: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 51 U.S.: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 52 U.S.: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 53 Canada: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 54 Canada: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 55 Canada: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 56 Canada: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 57 Canada: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 58 Canada: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 59 Europe: Epigenetics Market, by Country/Region, 2024-2036 (USD Million)
- Table 60 Europe: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 61 Europe: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 62 Europe: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 63 Europe: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 64 Europe: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 65 Europe: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 66 Germany: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 67 Germany: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 68 Germany: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 69 Germany: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 70 Germany: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 71 Germany: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 72 France: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 73 France: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 74 France: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 75 France: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 76 France: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 77 France: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 78 U.K.: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 79 U.K.: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 80 U.K.: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 81 U.K.: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 82 U.K.: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 83 U.K.: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 84 Italy: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 85 Italy: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 86 Italy: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 87 Italy: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 88 Italy: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 89 Italy: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 90 Spain: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 91 Spain: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 92 Spain: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 93 Spain: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 94 Spain: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 95 Spain: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 96 Rest of Europe: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 97 Rest of Europe: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 98 Rest of Europe: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 99 Rest of Europe: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 100 Rest of Europe: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 101 Rest of Europe: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 102 Asia-Pacific: Epigenetics Market, by Country/Region, 2024-2036 (USD Million)
- Table 103 Asia-Pacific: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 104 Asia-Pacific: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 105 Asia-Pacific: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 106 Asia-Pacific: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 107 Asia-Pacific: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 108 Asia-Pacific: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 109 China: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 110 China: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 111 China: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 112 China: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 113 China: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 114 China: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 115 Japan: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 116 Japan: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 117 Japan: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 118 Japan: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 119 Japan: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 120 Japan: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 121 India: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 122 India: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 123 India: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 124 India: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 125 India: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 126 India: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 127 Rest of Asia-Pacific: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 128 Rest of Asia-Pacific: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 129 Rest of Asia-Pacific: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 130 Rest of Asia-Pacific: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 131 Rest of Asia-Pacific: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 132 Rest of Asia-Pacific: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 133 Latin America: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 134 Latin America: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 135 Latin America: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 136 Latin America: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 137 Latin America: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 138 Latin America: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 139 Middle East & Africa: Epigenetics Market, by Offering, 2024-2036 (USD Million)
- Table 140 Middle East & Africa: Epigenetics Kits & Reagents Market, by Product, 2024-2036 (USD Million)
- Table 141 Middle East & Africa: Epigenetics Market, by Method, 2024-2036 (USD Million)
- Table 142 Middle East & Africa: Epigenetics Market for DNA Methylation, by Type, 2024-2036 (USD Million)
- Table 143 Middle East & Africa: Epigenetics Market, by Application, 2024-2036 (USD Million)
- Table 144 Middle East & Africa: Epigenetics Market, by End User, 2024-2036 (USD Million)
- Table 145 Epigenetics Market: Competitive Benchmarking, by Offering
- Table 146 Epigenetics Market: Competitive Benchmarking, by Method
- Table 147 Epigenetics Market: Market Ranking of Key Players, 2025
- Table 148 Merck KGaA: Product Portfolio
- Table 149 Merck KGaA: Strategic Developments
- Table 150 10x Genomics, Inc.: Product Portfolio
- Table 151 10x Genomics, Inc.: Strategic Developments
- Table 152 Thermo Fisher Scientific Inc.: Product Portfolio
- Table 153 Thermo Fisher Scientific Inc.: Strategic Developments
- Table 154 Illumina, Inc.: Product Portfolio
- Table 155 Illumina, Inc.: Strategic Developments
- Table 156 QIAGEN N.V.: Product Portfolio
- Table 157 QIAGEN N.V.: Strategic Developments
- Table 158 New England Biolabs, Inc.: Product Portfolio
- Table 159 New England Biolabs, Inc.: Strategic Developments
- Table 160 EpiCypher, Inc.: Product Portfolio
- Table 161 EpiCypher, Inc.: Strategic Developments
- Table 162 Pacific Biosciences of California, Inc.: Product Portfolio
- Table 163 Pacific Biosciences of California, Inc.: Strategic Developments
- Table 164 Bio-Rad Laboratories, Inc.: Product Portfolio
- Table 165 Bio-Rad Laboratories, Inc.: Strategic Developments
- Table 166 Revvity, Inc.: Product Portfolio
- Table 167 Revvity, Inc.: Strategic Developments
- Table 168 Active Motif, Inc.: Product Portfolio
- Table 169 Active Motif, Inc.: Strategic Developments
- Table 170 Zymo Research Corporation: Product Portfolio
- Table 171 Zymo Research Corporation: Strategic Developments
LIST OF FIGURES
List of Figures
- Figure 1 Research Process
- Figure 2 Primary Research Techniques
- Figure 3 Key Executives Interviewed
- Figure 4 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
- Figure 5 Market Sizing and Growth Forecast Approach
- Figure 6 Global Epigenetics Market Size: 2024, 2026 and 2036 (USD Million)
- Figure 7 Global Epigenetics Market: CAGR, by Segment, 2026-2036 (%)
- Figure 8 Global Epigenetics Market, by Offering, 2026 vs. 2036 (USD Million)
- Figure 9 Global Epigenetics Market, by Method, 2026 vs. 2036 (USD Million)
- Figure 10 Global Epigenetics Market, by Application, 2026 vs. 2036 (USD Million)
- Figure 11 Global Epigenetics Market, by End User, 2026 vs. 2036 (USD Million)
- Figure 12 Epigenetics Market, by Geography
- Figure 13 Global Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 14 Epigenetics: Key Milestones in Drugs, Diagnostics, Technologies and Epigenetic Editing, July 2024-SEPTEMBER 2026
- Figure 15 Factors Affecting Market Growth
- Figure 16 New Cancer Cases Worldwide, 2022 vs. 2050 (Million)
- Figure 17 Complete Remission Rates in Pivotal Trials of Approved Menin Inhibitors (%)
- Figure 18 Minimum DNA Input for Enzymatic Methylation Sequencing, Original EM-seq vs. EM-seq v2 (Nanograms)
- Figure 19 Cologuard Plus Performance in the BLUE-C Study (%)
- Figure 20 Merck KGaA Life Science: Organic Sales Growth, by Business Unit, 2025 (%)
- Figure 21 Galleri: FDA Advisory Committee Votes, September 2026
- Figure 22 List Prices of Selected Methylation-Based Tests and Sequencing (USD)
- Figure 23 Porter's Five Forces Analysis
- Figure 24 Global Epigenetics Market: Segment Landscape, by Offering, 2026 vs. 2036 (USD Million)
- Figure 25 Global Epigenetics Market, by Offering, 2026 vs. 2036 (USD Million)
- Figure 26 Global Epigenetics Kits & Reagents Market, by Product, 2026 vs. 2036 (USD Million)
- Figure 27 10x Genomics: Year-on-Year Revenue Change, by Category, Fourth Quarter 2025 (%)
- Figure 28 Pacific Biosciences Revenue, by Category, 2024 vs. 2025 (USD Million)
- Figure 29 Global Epigenetics Market: Segment Landscape, by Method, 2026 vs. 2036 (USD Million)
- Figure 30 Global Epigenetics Market: Growth and Size Matrix, by Method, 2026-2036
- Figure 31 Global Epigenetics Market, by Method, 2026 vs. 2036 (USD Million)
- Figure 32 Global Epigenetics Market for DNA Methylation, by Type, 2026 vs. 2036 (USD Million)
- Figure 33 Relative Sequencing Required for Genome-Wide Methylation Analysis: Whole-Genome Approaches vs. meCUT&RUN (Index)
- Figure 34 Global Epigenetics Market: Value Composition, by Application, 2026
- Figure 35 Global Epigenetics Market, by Application, 2026 vs. 2036 (USD Million)
- Figure 36 Shield Blood-Based Colorectal Cancer Screening Test Volume, 2025 vs. 2026
- Figure 37 Global Epigenetics Market: Segment Landscape, by End User, 2026 vs. 2036 (USD Million)
- Figure 38 Global Epigenetics Market, by End User, 2026 vs. 2036 (USD Million)
- Figure 39 Participants in Studies Supporting the Galleri Premarket Approval Application
- Figure 40 Epigenetics Market, by Geography
- Figure 41 Epigenetics Market: Country Growth and Size Matrix, 2026-2036
- Figure 42 Global Epigenetics Market, by Region, 2026 vs. 2036 (USD Million)
- Figure 43 North America: Epigenetics Market, by Country/Region, 2026 vs. 2036 (USD Million)
- Figure 44 U.S.: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 45 Canada: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 46 Europe: Epigenetics Market, by Country/Region, 2026 vs. 2036 (USD Million)
- Figure 47 Germany: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 48 France: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 49 U.K.: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 50 Italy: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 51 Spain: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 52 Rest of Europe: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 53 Asia-Pacific: Epigenetics Market, by Country/Region, 2026 vs. 2036 (USD Million)
- Figure 54 China: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 55 Japan: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 56 India: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 57 Rest of Asia-Pacific: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 58 Latin America: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 59 Middle East & Africa: Epigenetics Market Size, 2024-2036 (USD Million)
- Figure 60 Epigenetics Market: Strategic Developments, by Company and Approach, January 2025-SEPTEMBER 2026
- Figure 61 Epigenetics Market: Number of Strategic Developments, by Approach, January 2025-SEPTEMBER 2026
- Figure 62 Epigenetics Market: Competitive Dashboard
- Figure 63 Merck KGaA: Financial Snapshot (2025)
- Figure 64 Merck KGaA: SWOT Analysis
- Figure 65 10x Genomics, Inc.: Financial Snapshot (2025)
- Figure 66 10x Genomics, Inc.: SWOT Analysis
- Figure 67 Thermo Fisher Scientific Inc.: Financial Snapshot (2025)
- Figure 68 Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 69 Illumina, Inc.: Financial Snapshot (2025)
- Figure 70 Illumina, Inc.: SWOT Analysis
- Figure 71 QIAGEN N.V.: Financial Snapshot (2025)
- Figure 72 QIAGEN N.V.: SWOT Analysis
- Figure 73 New England Biolabs, Inc.: SWOT Analysis
- Figure 74 EpiCypher, Inc.: SWOT Analysis
- Figure 75 Pacific Biosciences of California, Inc.: Financial Snapshot (2025)
- Figure 76 Pacific Biosciences of California, Inc.: SWOT Analysis
- Figure 77 Bio-Rad Laboratories, Inc.: Financial Snapshot (2025)
- Figure 78 Bio-Rad Laboratories, Inc.: SWOT Analysis
- Figure 79 Revvity, Inc.: Financial Snapshot (2025)
- Figure 80 Revvity, Inc.: SWOT Analysis
- Figure 81 Active Motif, Inc.: SWOT Analysis
- Figure 82 Zymo Research Corporation: SWOT Analysis
